Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02079168 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
A Phase 2 study, sponsored by RXi Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02079168 is a Phase 2 study that has completed, run by RXi Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT02079168, a Phase 2 study, has completed, sponsored by RXi Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.
Interventions
- DRUG Placebo
- DRUG RXI-109
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02079168
The ClinicalTrials.gov registry entry for NCT02079168 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RXi Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02079168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02079168 about?
NCT02079168 is a clinical study titled "A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults". To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.
What is the current status of trial NCT02079168?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2014-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02079168?
The interventions under investigation include: Placebo (DRUG), RXI-109 (DRUG).
Who is sponsoring clinical trial NCT02079168?
This trial is sponsored by RXi Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.